P2RY12 and cancer: In-hospital use of P2Y12 inhibitors (47.6 vs. 92.9%, p < 0.001), proton pump inhibitors (38.1 vs. 74.3%, p = 0.001), and statins (66.7 vs. 87.6%, p < 0.05) was less frequent in cancer MINOCA than in cancer MI-CAD.